NCT02923934 2024-07-24
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Olivia Newton-John Cancer Research Institute
Phase 2 Completed
Olivia Newton-John Cancer Research Institute
Fondazione per la Medicina Personalizzata
Jules Bordet Institute